Butyrate as a potential therapeutic agent for neurodegenerative disorders
Neurochemistry International · 2024-06 · 176 · 105745
DOI: 10.1016/j.neuint.2024.105745 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Neurochemistry International, 2024-06. Verfasst von Prapti Chakraborty und 2 weiteren Autor:innen. Beteiligte Einrichtung: Macquarie University Motor Neuron Disease Research Centre, Macquarie Medical School, Faculty of Medicine, Health and Human Sciences, Macquarie Univer…. Hauptthemen laut MEDLINE: Butyrates, Gastrointestinal Microbiome, Neurodegenerative Diseases. Die Arbeit wurde bisher 43-mal zitiert (Crossref) und nennt 265 Literaturangaben. Gefördert von: National Health and Medical Research Council.
Abstract (Originalsprache)
Maintaining an optimum microbial community within the gastrointestinal tract is intricately linked to human metabolic, immune and brain health. Disturbance to these microbial populations perturbs the production of vital bioactive compounds synthesised by the gut microbiome, such as short-chain fatty acids (SCFAs). Of the SCFAs, butyrate is known to be a major source of energy for colonocytes and has valuable effects on the maintenance of intestinal epithelium and blood brain barrier integrity, gut motility and transit, anti-inflammatory effects, and autophagy induction. Inducing endogenous butyrate production is likely to be beneficial for gut-brain homeostasis and for optimal neuronal function. For these reasons, butyrate has gained interest as a potential therapy for not only metabolic and immunological disorders, but also conditions related to the brain, including neurodegenerative diseases. While direct and indirect sources of butyrate, including prebiotics, probiotics, butyrate pro-drugs and glucosidase inhibitors, offer a promising therapeutic avenue, their efficacy and dosage in neurodegenerative conditions remain largely unknown. Here, we review current literature on effects of butyrate relevant to neuronal function, the impact of butyrate in a range of neurodegenerative diseases and related treatments that may have potential for the treatment of neurodegenerative diseases.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Macquarie University Motor Neuron Disease Research Centre, Macquarie Medical School, Faculty of Medicine, Health and Human Sciences, Macquarie University, Sydney, Australia.
- School of Natural Sciences, Macquarie University, NSW, 2109, Australia; ARC Training Centre for Facilitated Advancement of Australia's Bioactives, Macquarie University, NSW, 2109, Australia.
- Macquarie University Motor Neuron Disease Research Centre, Macquarie Medical School, Faculty of Medicine, Health and Human Sciences, Macquarie University, Sydney, Australia. Electronic address: angela.laird@mq.edu.au.
Förderung
- National Health and Medical Research Council
Zitieren
APA
Chakraborty, P., Gamage, H. K. A. H., & Laird, A. S. (2024). Butyrate as a potential therapeutic agent for neurodegenerative disorders. Neurochemistry International, 176, 105745. https://doi.org/10.1016/j.neuint.2024.105745
Vancouver
Chakraborty P, Gamage HKAH, Laird AS. Butyrate as a potential therapeutic agent for neurodegenerative disorders. Neurochemistry International. 2024;176:105745. doi:10.1016/j.neuint.2024.105745
BibTeX
@article{Chakraborty2024,
author = {Chakraborty, Prapti and Gamage, Hasinika K A H and Laird, Angela S},
title = {Butyrate as a potential therapeutic agent for neurodegenerative disorders},
journal = {Neurochemistry International},
year = {2024},
volume = {176},
pages = {105745},
doi = {10.1016/j.neuint.2024.105745}
}
EUVIMED